Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France

A. COUSIEN ; V. C. TRAN ; S. DEUFFIC-BURBAN ; M. JAUFFRET-ROUSTIDE ; G. MABILEAU ; J. S. DHERSIN ; Y. YAZDANPANAH | 2018
Dans Journal of Viral Hepatitis (Vol.25, n°10, October 2018) Article : Périodique

Direct-acting antivirals (DAAs) represent an opportunity to improve hepatitis C virus (HCV) care cascade. This, combined with improved harm reduction interventions may lead to HCV elimination especially in people who inject drugs (PWID). We asse[...]

Plus d'info

Ajouter à la sélection

Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs

A. COUSIEN ; V. C. TRAN ; S. DEUFFIC-BURBAN ; M. JAUFFRET-ROUSTIDE ; J. S. DHERSIN ; Y. YAZDANPANAH | 2016
Dans Hepatology (Vol.63, n°4, April 2016) Article : Périodique

Background: Hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (PWID) populations, often above 60%. Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming available for HCV treatment. This [...]

Plus d'info

Ajouter à la sélection